Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection
- 20 January 2003
- reference entry
- review article
- Published by Wiley
- No. 2,p. CD003508
- https://doi.org/10.1002/14651858.cd003508
Abstract
The prevention and early treatment of infections are the mainstay of the medical management of the majority of children with HIV infection, who live in low income countries without access to antiretroviral drugs. Cotrimoxazole is cheap and effective against a wide range of organisms, including Pneumocystis carinii pneumonia (PCP) which is an important cause of death and illness in the first year of life. It is safe with relatively few side-effects. Diagnosis of HIV in children is complicated by the presence of maternal antibodies in early life and providing prophylaxis based initially on maternal status is one possible solution. However routine prophylactic treatment is difficult to deliver in low-resource settings, and could also lead to increased resistance to the drug. To assess the effects of routinely administered cotrimoxazole on death and illness episodes in children with HIV infection, and in infants of HIV infected mothers. We searched the Cochrane HIV/AIDS registry, MEDLINE, the Cochrane Controlled Trials Register, LILACS, AIDSLINE, AIDSTRIALS and AIDSDRUGS databases, and proceedings and abstracts from AIDS and TB conferences (search date July 2001). We checked reference lists of pertinent articles, and contacted pharmaceutical companies and experts in the field. Randomised or quasi randomised trials comparing routinely administered cotrimoxazole versus placebo or no treatment in children (age less than 13 years) with HIV infection, or children less than 18 months with HIV infected mothers. Two reviewers independently assessed trial eligibility and quality. No studies were found that fulfilled the selection criteria. No evidence from controlled trials was found of the effect of cotrimoxazole prophylaxis in HIV-infected children.Keywords
This publication has 10 references indexed in Scilit:
- Cotrimoxazole prophylaxis for opportunistic infections in adults with HIVCochrane Database of Systematic Reviews, 2003
- Morbidity Among Human Immunodeficiency Virus-1-Infected and -Uninfected African ChildrenPublished by American Academy of Pediatrics (AAP) ,2000
- Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virusThe Pediatric Infectious Disease Journal, 2000
- Natural History of Human Immunodefiency Virus Type 1 Infection in Children: A Five-Year Prospective Study in RwandaPublished by American Academy of Pediatrics (AAP) ,1999
- Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trialThe Lancet, 1999
- Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trialThe Lancet, 1999
- Pulmonary manifestations in HIV seropositivity and malnutrition in ZimbabweArchives of Disease in Childhood, 1997
- Mother-to-Child Transmission of the Human Immunodeficiency VirusNew England Journal of Medicine, 1995
- Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDSJAMA, 1988
- Pneumocystis cariniiPneumonia and Mucosal Candidiasis in Previously Healthy Homosexual MenNew England Journal of Medicine, 1981